Overnutrition, mTOR signaling, and cardiovascular diseases

Am J Physiol Regul Integr Comp Physiol. 2014 Nov 15;307(10):R1198-206. doi: 10.1152/ajpregu.00262.2014. Epub 2014 Sep 24.

Abstract

The prevalence of obesity and associated medical disorders has increased dramatically in the United States and throughout much of the world in the past decade. Obesity, induced by excess intake of carbohydrates and fats, is a major cause of Type 2 diabetes, hypertension, and the cardiorenal metabolic syndrome. There is emerging evidence that excessive nutrient intake promotes signaling through the mammalian target of rapamycin (mTOR), which, in turn, may lead to alterations of cellular metabolic signaling leading to insulin resistance and obesity-related diseases, such as diabetes, cardiovascular and kidney disease, as well as cancer. While the pivotal role of mTOR signaling in regulating metabolic stress, autophagy, and adaptive immune responses has received increasing attention, there remain many gaps in our knowledge regarding this important nutrient sensor. For example, the precise cellular signaling mechanisms linking excessive nutrient intake and enhanced mTOR signaling with increased cardiovascular and kidney disease, as well as cancer, are not well understood. In this review, we focus on the effects that the interaction between excess intake of nutrients and enhanced mTOR signaling have on the promotion of obesity-associated diseases and potential therapeutic strategies involving targeting mTOR signaling.

Keywords: cardiorenal metabolic syndrome; cardiovascular disease; insulin resistance; mammalian target of rapamycin; obesity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / immunology
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / physiopathology
  • Cardiovascular Diseases / prevention & control
  • Energy Intake
  • Energy Metabolism
  • Humans
  • Insulin Resistance
  • Molecular Targeted Therapy
  • Obesity / complications*
  • Obesity / drug therapy
  • Obesity / immunology
  • Obesity / metabolism
  • Obesity / physiopathology
  • Ribosomal Protein S6 Kinases / metabolism
  • Risk Factors
  • Signal Transduction* / drug effects
  • TOR Serine-Threonine Kinases / metabolism*

Substances

  • Ribosomal Protein S6 Kinases
  • TOR Serine-Threonine Kinases